Deep Dive
来自我们记者的行业洞察
The Future of Diabetes Treatment: New Drug Development or Optimizing Existing Diagnosis and Treatment Pathways?
The U.S. FDA's approval of Novo Nordisk's new drug Rybelsus marks a new stage in innovation for type 2 diabetes medications. However, amid high drug prices and requirements for evidence of cardiovascular benefits, pharmaceutical giants and clinical experts are divided on the future direction: should they continue developing more precise glucose-lowering drugs, or should they focus on improving the accessibility and implementation of existing diagnosis and treatment?
Louisiana's Hepatitis C Drug Subscription Model: Lessons from a Drug Pricing Experiment
Louisiana reached a five-year subscription agreement with Gilead for hepatitis C drugs, securing unlimited supply of Harvoni for approximately $60 million per year. The model was led by state Health Secretary Rebekah Gee, following three years of negotiations and multi-party maneuvering. This article analyzes its policy design, industry resistance, and significance as a model for other states.
Women CEOs account for less than 10% in the biotech industry, industry organization BIO faces reform pressure
An analysis by BioPharma Dive of 180 leading biotech companies shows that only 15 were led by women in 2023, accounting for less than 10%. Veracyte CEO Bonnie Anderson called this figure "astonishingly low and absurd." BIO, the industry's main lobbying organization, has more than doubled its diversity committee budget but has not yet set a target for the proportion of female CEOs. Several industry executives have called for more proactive action.
From "Manpower Outsourcing" to "Data Experts": Observations on Role Transformation in the CRO Industry
Pharmaceutical companies are pursuing better-designed, lower-cost clinical trials, driving contract research organizations (CROs) to transform into data service providers. Over the past year, companies such as Thermo Fisher, Cambrex, and Charles River Laboratories have invested hundreds of millions of dollars to expand related businesses. Regulatory signals and the demand for real-world data are becoming key catalysts for this transformation.
Neurocrine's Rise and Fall: CEO Kevin Gorman on the Company's Journey from Rock Bottom to Revival
A decade ago, Neurocrine was on the brink of collapse after its lead drug candidates were repeatedly rejected and funding ran tight, with staff slashed from nearly 600 to 67. Today, the San Diego-based biotech has two marketed drugs and a market cap of about $7.8 billion. In an exclusive interview, CEO Kevin Gorman looks back on the company's full journey from its founding in the late 1980s, its collapse in the 2000s, to its recent revival, while analyzing industry shifts, lessons from FDA collaborations, and the future competitive landscape.
The era of gene therapy has arrived, and challenges follow
Gene therapy is moving from the laboratory to the clinic, but issues such as high pricing, difficulties in medical insurance reimbursement, the complexity of treating polygenic diseases, and regulatory balance are testing the sustainability of this emerging field.
NASH Market Size Remains a Mystery: From 30 Million to Billions of Dollars, Industry Diverges Sharply
Estimates of the patient population and market potential for nonalcoholic steatohepatitis (NASH) are fraught with significant uncertainty. The National Institutes of Health estimates a prevalence rate of 3%-12% among U.S. adults, but the studies it relies on include fewer than 400 participants. Investment banks' market forecasts range from $7 billion to $20 billion, far below the $35 billion opportunity claimed by pharmaceutical companies. Diagnostic challenges, patient heterogeneity, and payer resistance make the commercialization of NASH drugs difficult.